Hospitalized patients with opioid use disorder who present with acute pain are challenging
to manage. Without any treatment, their mortality in the first 28 days after discharge is …

Background and Objectives In some countries, particularly the United States and Canada,
there has been a growing problem of opioid dependence associated with the treatment of …

Background Virtually delivered healthcare (telehealth, telemedicine) has the potential to
reduce gaps in access to opioid agonist therapy (OAT). Barriers to accessing OAT such as …

Background Individuals with opioid use disorder (OUD) use the emergency department (ED)
at high rates. Medication treatment for OUD (MOUD) is associated with reduced ED …

Buprenorphine has become an important medication in the context of the ongoing opioid
epidemic. However, complex pharmacologic properties and varying government regulations …

Background Buprenorphine may provide superior analgesia to full opioid agonist therapy
and reverse the effects of opioid-induced hyperalgesia, while having a favorable safety …

A growing body of literature describes the use of buprenorphine for the treatment of chronic
pain in people with sickle cell disease. The experiences of people with sickle cell disease …

Background Butorphanol is marketed as a treatment for migraines; however, evidence
suggests that the harms of its use exceed the benefits. The short half-life of butorphanol …

An organized and integrated acute pain management service (APMS) is a requirement for
delivery of high-quality pain management in an increasingly complex health care …

One in 5 Canadians lives with chronic pain, and as our population ages, the prevalence and
impact of this disease are expected to grow. 1 A multimodal combination of pharmacologic …